QIAGEN’s next-generation QIAstat-Dx system delivers fast, cost-effective diagnosis of gastrointestinal syndromes
Hilden, Germany, and Germantown, Maryland, October 15, 2018– QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the European rollout of its next-generation QIAstat-Dx panel for one-step, fully integrated molecular analysis of gastrointestinal (GI) syndromes. The multiplex gastrointestinal panel, which QIAGEN has upgraded to now include comprehensive viral coverage detects the 24 most common viral,... Read more